Such stuff as dreams are made on: mediator-directed therapy in sepsis.
about
Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsisDrotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.Biomarkers for Sepsis: What Is and What Might Be?Clinical review: sepsis and septic shock--the potential of gene arraysThe platelet activating factor (PAF) signaling cascade in systemic inflammatory responsesDual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases-C3 or C5 emerge together with CD14 as promising targetsEvasion of inflammasome activation by microbial pathogensA robust scoring system to evaluate sepsis severity in an animal model.Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency.Decrease of plasma platelet-activating factor acetylhydrolase activity in lipopolysaccharide induced mongolian gerbil sepsis model.CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs.Pathophysiology and treatment of septic shock in neonates.New modalities in treating pneumococcal pneumonia.Redox state of pentraxin 3 as a novel biomarker for resolution of inflammation and survival in sepsis.Anti-endotoxin agents. 2. Pilot high-throughput screening for novel lipopolysaccharide-recognizing motifs in small moleculesMonitoring immune dysfunctions in the septic patient: a new skin for the old ceremony.The influence of statin exposure on inflammatory markers in patients with early bacterial infection: pilot prospective cohort study.Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis.Anti-endotoxin agents. 1. Development of a fluorescent probe displacement method optimized for the rapid identification of lipopolysaccharide-binding agents.Bacterial clearance is improved in septic mice by platelet-activating factor-acetylhydrolase (PAF-AH) administration.Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis.Toll-like receptor-mediated inflammatory signaling reprograms cardiac energy metabolism by repressing peroxisome proliferator-activated receptor γ coactivator-1 signaling.Genome-wide transcription profiling of human sepsis: a systematic review.Recent developments in the identification of novel therapeutic targets for the treatment of patients with sepsis and septic shock.C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-center prospective observational study.A history of pediatric critical care medicine.Emerging drugs for the treatment of sepsis.Current trends in inflammatory and immunomodulatory mediators in sepsisBacterial clearance in septic mice is modulated by MCP-1/CCL2 and nitric oxide.Development of a genomic metric that can be rapidly used to predict clinical outcome in severely injured trauma patients.Risk factors for acute organ failure in intensive care unit patients who receive respiratory support in the absence of non-respiratory organ failure: an international prospective cohort studyIs there value in plasma cytokine measurements in patients with severe trauma and sepsis?A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice.Inhibition of complement and CD14 attenuates the Escherichia coli-induced inflammatory response in porcine whole blood.The alternative complement pathway revisited.The role of corticosteroids in severe community-acquired pneumonia: a systematic review.Potential of immunomodulatory agents for prevention and treatment of neonatal sepsis.Shedding of tumor necrosis factor receptor 1 induced by protein A decreases tumor necrosis factor alpha availability and inflammation during systemic Staphylococcus aureus infection.The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomesNovel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response.
P2860
Q24568212-A0693C1C-C82A-45E6-A6E1-2A1829CFF8DEQ24810495-4BFB48A1-9C9C-4184-838C-769D45428F43Q26785255-F4993AB6-1D00-4E46-B7DE-43E8CB40D3A3Q26864138-E9323E47-0703-43D5-B1C4-F3E304092C98Q27693180-3912ECAD-8D26-46E1-8A25-6A350FFD8061Q28077955-27DBFB4D-DCF9-4C58-BEAB-52BE603E948FQ28082757-7EA1CC8A-23B2-4E6A-9EA1-A64DFC04E83FQ30578164-CA432407-09D5-446B-8AA5-4F0C993D261FQ33373012-7376132C-FBFF-48B1-99CE-35F6CD9DD42CQ33532642-6D28122D-0B03-466A-BDF5-155504EC4140Q33694581-B562A168-4DCE-4A42-8248-297A1B108798Q33940492-F3D60E0F-7E28-444F-9EF9-D83D9E2AADFFQ34185386-2C817264-9840-497C-B17F-E4946D0F357CQ34303331-9907E05C-92DF-41C7-86B6-AB71655E165BQ34333751-7B081EC2-E3A6-4CFD-AA92-9A5620B3FC08Q34585151-2C96581F-C01D-41F2-8F50-267EA2B4AEE9Q34636358-DAB95B33-9255-4B22-B744-44E11D959F43Q34866465-0B0EA92D-4B3F-49C0-9CBE-E98132017988Q34977410-BB6D7B33-9FA5-4B02-9BC9-6C5895AAF345Q34999226-8A58A7D4-B2D0-4375-B220-586A7747E0A9Q34999600-5F4C08C5-247E-41DC-BD45-ED56D76B0330Q35129034-9F56D696-7CA7-40A9-9DED-CAAD6DE0644EQ35561247-7487EEFD-51F7-4FD1-A5B7-0051E2C5DAA3Q35585111-10B77A7C-80A5-4064-B6C8-E5FFC8B689C4Q36070410-546521B6-1FD9-43DD-8173-CED72DFE03FDQ36267748-7B0A9C8D-482C-4B8D-9C77-F00E40AB8E65Q36407391-8A72DD9C-FF7D-4131-8FC0-31FC85313BF1Q36628592-036EE85C-32D9-4598-9BE4-C94CDAC20A66Q36668647-F430C3E3-E3F0-469B-BD46-2F56C876BBD2Q36838630-177BBBD1-8015-4E52-A428-A825F7AA34A6Q36925841-4D1CEC7E-787C-4768-840E-B492D4E9D893Q36931182-B012ED42-922C-45B4-BF2E-841ACC21FDB9Q37002272-32C5E4F0-70EE-4502-82B9-1ED588EAF200Q37075440-5CA8FDF5-167C-44B7-A782-15D76B8AC490Q37141297-7495E9C5-1EEC-46FE-BD94-F515D9A9ABFCQ37189110-2612C3A1-186C-4877-A558-C0DA715E5A1BQ37260284-A865A069-4557-4F4D-8BF4-226CFA2F97CEQ37264838-B6973688-D30D-4A73-944B-82296C2FE1A3Q37279933-D5C1DD0B-7E75-4FBD-8954-4EB3E414EB65Q37367885-FD8B0848-C7AA-4F4B-88BE-F2AF9E5B6F0F
P2860
Such stuff as dreams are made on: mediator-directed therapy in sepsis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Such stuff as dreams are made on: mediator-directed therapy in sepsis.
@ast
Such stuff as dreams are made on: mediator-directed therapy in sepsis.
@en
type
label
Such stuff as dreams are made on: mediator-directed therapy in sepsis.
@ast
Such stuff as dreams are made on: mediator-directed therapy in sepsis.
@en
prefLabel
Such stuff as dreams are made on: mediator-directed therapy in sepsis.
@ast
Such stuff as dreams are made on: mediator-directed therapy in sepsis.
@en
P356
P1476
Such stuff as dreams are made on: mediator-directed therapy in sepsis.
@en
P2093
John C Marshall
P2888
P304
P356
10.1038/NRD1084
P577
2003-05-01T00:00:00Z